Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.
浙江昂拓萊司生物技術(shù)有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!